Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study

Farhad Ravandi, MBBS, Asad Bashey, MD PhD, Wendy Stock, MD, James M. Foran, MD, Raya Mawad, MD, Daniel Egan, MD, William Blum, MD, Allen Yang, MD PhD, Alessandro Pastore, MD, Chelsea Johnson, BSN,RN, Shuo Zheng, Musa Yilmaz, MD, Alice S. Mims, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-134746

Published: 2020

Journal Articles

Spliceosomal Dysfunction Is a Critical Mediator of IDH2 Mutant Leukemogenesis

Blood (2017) 130 (Supplement 1): 473.

https://doi.org/10.1182/blood.V130.Suppl_1.473.473

Published: 2017

Journal Articles

The Mutational Landscape and Immune Microenvironment of Primary Intestinal Follicular Lymphoma (PIFL)

Johannes Hellmuth, MD, Abner Louissaint, MD PhD, Monika Szczepanowski, PhD, Sarah Häbe, MD, Alessandro Pastore, MD, Annette M. Staiger, PhD, Sylvia Hartmann, Robert Kridel, Matthew D. Ducar, MS, Peter Koch, MD, Martin Dreyling, MD PhD, Martin-Leo Hansmann, MD, German Ott, MD, Andreas Rosenwald, MD, Randy D. Gascoyne, MD, David M. Weinstock, MD, Wolfgang Hiddemann, MD PhD, Wolfram Klapper, MD, Oliver Weigert, MD

Blood (2017) 130 (Supplement 1): 2735.

https://doi.org/10.1182/blood.V130.Suppl_1.2735.2735

Published: 2017

Journal Articles

Integrative Epigenomics Reveals Novel Chronic Lymphocytic Leukemia-Specific Chromatin States Associated with Epigenetic and Transcriptional Heterogeneity

Alessandro Pastore, MD, Federico Gaiti, PhD, Sydney X. Lu, MDPhD, Omar Abdel-Wahab, MD, Dan A. Landau, MD

Blood (2017) 130 (Supplement 1): 1723.

https://doi.org/10.1182/blood.V130.Suppl_1.1723.1723

Published: 2017

Journal Articles

Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma

Christian Grommes, MD, Alessandro Pastore, MD, Igor Gavrilovic, MD, Thomas Kaley, MD, Craig Nolan, MD, Antonio M. Omuro, MD, Julia Wolfe, Elena Pentsova, MD, Vaois Hatzoglou, MD, Ingo Mellinghoff, MD, Lisa DeAngelis, MD

Blood (2016) 128 (22): 783.

https://doi.org/10.1182/blood.V128.22.783.783

Published: 2016

Journal Articles

ASXL2 Is a Novel Mediator of RUNX1-ETO Transcriptional Function and Collaborates with RUNX1-ETO to Promote Leukemogenesis

Jean-Baptiste Micol, MD, Nicolas Duployez, Alessandro Pastore, MD, Robert Williams, Eunhee Kim, PhD, Stanley Lee, Benjamin Durham, MD PhD, Young Rock Chung, MS, Hana Cho, Claude Preudhomme, Omar Abdel-Wahab

Blood (2015) 126 (23): 302.

https://doi.org/10.1182/blood.V126.23.302.302

Published: 2015

Journal Articles

Disruptive ARID1A Mutations in Follicular Lymphoma Impair DNA Repair Efficiency and Are Associated with Favorable Outcome in Patients Receiving First-Line Immunochemotherapy

Deepak Bararia, PhD, Michael Heide, Robert S. Welner, PhD, Tatiana Romashova, Alessandro Pastore, MD, Radhika Mathur, Randy D. Gascoyne, Robert Kridel, MD MPH, Boris G. Willson, PhD, Charles W.M. Roberts, MD PhD, Wolfgang Hiddemann, MD PhD, David M Weinstock, MD, Oliver Weigert, MD

Blood (2015) 126 (23): 571.

https://doi.org/10.1182/blood.V126.23.571.571

Published: 2015

Journal Articles

STAT6 Is Recurrently and Significantly Mutated in Follicular Lymphoma and Enhances the IL-4 Induced Expression of Membrane-Bound and Soluble CD23

Michael W Bösl, Elisa Osterode, Deepak Bararia, PhD, Alessandro Pastore, MD, Anette M Staiger, German Ott, MD, Monika Szczepanowski, PhD, Wolfram Klapper, MD, Andreas Rosenwald, MD, Wolfgang Hiddemann, MD, Oliver Weigert, MD

Blood (2015) 126 (23): 3923.

https://doi.org/10.1182/blood.V126.23.3923.3923

Published: 2015

Journal Articles

TRAIL Receptor 1 and TRAIL Receptor 2 Monoclonal Antibodies Induce Apoptosis and Increase Susceptibility to Cytostatic Agents in Mantle Cell Lymphoma.

Malte Rieken, MD, Alessandro Pastore, MD, Oliver Weigert, MD, Marc Weinkauf, MD, Grit Hutter, MD, Yvonne Zimmermann, MD, Wolfgang Hiddemann, MD, Martin Dreyling, MD

Blood (2006) 108 (11): 4751.

https://doi.org/10.1182/blood.V108.11.4751.4751

Published: 2006

NARROW

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study

Spliceosomal Dysfunction Is a Critical Mediator of IDH2 Mutant Leukemogenesis

The Mutational Landscape and Immune Microenvironment of Primary Intestinal Follicular Lymphoma (PIFL)

Integrative Epigenomics Reveals Novel Chronic Lymphocytic Leukemia-Specific Chromatin States Associated with Epigenetic and Transcriptional Heterogeneity

Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma

ASXL2 Is a Novel Mediator of RUNX1-ETO Transcriptional Function and Collaborates with RUNX1-ETO to Promote Leukemogenesis

Disruptive ARID1A Mutations in Follicular Lymphoma Impair DNA Repair Efficiency and Are Associated with Favorable Outcome in Patients Receiving First-Line Immunochemotherapy

STAT6 Is Recurrently and Significantly Mutated in Follicular Lymphoma and Enhances the IL-4 Induced Expression of Membrane-Bound and Soluble CD23

TRAIL Receptor 1 and TRAIL Receptor 2 Monoclonal Antibodies Induce Apoptosis and Increase Susceptibility to Cytostatic Agents in Mantle Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only